Merck: FDA accepts Recarbrio for review

(CercleFinance.com) - Merck said on Monday that its Recarbrio treatment for pneumonia has been accepted for review by the US FDA and could be approved in early June.


The Food and Drug Administration has accepted for review a supplemental new drug application (sNDA) for the drug to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Gram-negative microorganisms.

The decision date has been set on 4 June, Merck said.

Recarbrio was initially approved by the FDA in 2019 for the treatment of complicated urinary tract infections.

Copyright (c) 2020 CercleFinance.com. All rights reserved.